


METASTATIC GASTROESOPHAGEAL CANCER


Personalized TumorGraft™ case study: 56-year-old male with metastatic gastroesophageal cancer who had 2 prior regimens¹

PERSONALIZED TUMORGRAFT™ RESPONSE TO DRUG TESTING INFORMED TREATMENT DECISIONS

First round of drug testing (third line of treatment)



Second round of drug testing (fourth line of treatment)




- Third round of drug testing demonstrated additional activity with Ixabepilone


¹Data on file. Champions Oncology.

PATIENT RESPONDED TO BOTH LINES OF THERAPY WITH NORMALIZED CEA LEVELS

Response to 3rd-line treatment for liver metastases



CEA level results following third- and fourth-line treatment



Case study conclusion

- Patient responded to four courses of Champions-guided therapy
- Survival extended 32 months in late-line therapy



Personalized Oncology Solutions

Champions Oncology, Inc.
One University Plaza, Suite 307
Hackensack, NJ 07604
Phone: 201.808.8400

www.ChampionsOncology.com

© Champions Oncology 2011